Fig. 4: Canine tumors share many of the same major gene and pathway alterations as their human counterparts.
From: Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds
Each panel of a–g compares the mutation recurrence of a gene or pathway in a tumor type between the two species. Human breast cancer (BRCA) (a), pediatric and adult GLM (b), diffuse large B-cell lymphoma (DLBCL) (c), TCL (d), mucosal melanoma (MM) (e), OSA (f) and angiosarcoma (AS) (g) are from published studies (see text). Shown are curated pathways (10 total) from a TCGA pan-cancer publication46, as well as genes mutated in ≥10 tumors and ≥10% (for pathway genes) or 20% (for non-pathway genes) of all tumors in a tumor type in either species. Genes and pathways with the mutation frequency that are significantly different (q < 0.05 from Fisher exact tests followed by multiple testing correction60) and have ≥2-fold changes between the two species are considered different. Source data are provided as a Source Data file.
